SARS-CoV-2 belongs to the family of enveloped, single-strand RNA viruses known as
Betacoronavirus in Coronaviridae, first reported late 2019 in China. It has since been …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is characterized by a burst
in the upper respiratory portal for high transmissibility. To determine human neutralizing …

Remdesivir is an antiviral agent that has shown broad‐spectrum activity, including against
severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Clinical trials investigating …

Background: The inflammatory reaction is the main cause of acute respiratory distress
syndrome and multiple organ failure in patients with Coronavirus disease 2019, especially …

Newly emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused a
global pandemic with astonishing mortality and morbidity. The high replication and …

The COVID-19 pandemic has presented a serious challenge to the hepatology community,
particularly healthcare professionals and patients. While the rapid development of safe and …

The clinical implications of COVID-19 have changed since SARS-CoV-2 first emerged in
humans. The current high levels of population immunity, due to prior infection and/or …

OBJECTIVES: Remdesivir shortens time to recovery in adults with severe coronavirus
disease 2019 (COVID-19), but its efficacy and safety in children are unknown. We describe …

Genetic variation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
resulted in the emergence and rapid spread of multiple variants throughout the pandemic, of …

COVID-19 is an infectious disease caused by a novel β-coronavirus, belonging to the same
subgenus as the Severe Acute Respiratory Syndrome (SARS) virus. Remdesivir, an …